The Lancet Oncology, 22(10), 1378-1390. Lancet Publishing Group Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9 The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)